In re Target Corporation BPO Sales and Marketing Litigation

Summary

The United States District Court for the District of Minnesota addresses Target's motion to dismiss a putative class action involving benzoyl peroxide acne products allegedly containing or degrading into benzene. The court holds that plaintiffs plausibly alleged Article III standing, CAFA jurisdiction, and several state-law claims, while concluding that they lacked standing to seek prospective injunctive or declaratory relief. The court also rejects FDCA preemption and primary-jurisdiction arguments but dismisses or rejects certain theories and claims, including the current-good-manufacturing-practices theory, negligent misrepresentation, and unjust enrichment.

Holdings

1. Plaintiffs plausibly alleged Article III injury because the Up&Up products they purchased manifested the alleged benzene defect. The complaint alleged that every tested Up&Up product contained benzene at day zero and that Target manufactured its Up&Up products in the same manner, permitting a plausible inference that the purchased products also contained benzene.
2. Plaintiffs lacked standing to seek forward-looking injunctive or declaratory relief because they alleged no plausible prospect of future interactions with Target, including future purchases.
3. Plaintiffs plausibly alleged the Class Action Fairness Act's jurisdictional prerequisites, including minimal diversity, a proposed class exceeding 100 members, and an amount in controversy exceeding $5 million.
4. The FDCA did not preempt plaintiffs' state-law theory that Target's Up&Up products were misbranded because their labels failed to disclose the presence of benzene.
5. Plaintiffs' adulteration theory survived dismissal because the complaint plausibly alleged that the Up&Up products they purchased contained benzene.
6. Plaintiffs' current-good-manufacturing-practices theory failed because the complaint alleged only legal conclusions and did not plead facts showing how Target violated particular cGMP requirements.
7. The primary-jurisdiction doctrine did not warrant dismissal or a stay because FDA action on Valisure's Citizen Petition was unlikely to resolve the legal or factual issues in plaintiffs' damages claims, and the issues were not beyond the court's conventional experience.
8. The economic-loss rules of California, Illinois, and Nebraska barred plaintiffs' negligent-misrepresentation and negligent-omission claims because plaintiffs alleged only economic losses from purchasing allegedly defective products and did not seek damages for personal injury or damage to other property.
9. Plaintiffs' unjust-enrichment claim did not survive because they failed to plausibly allege that they might lack an adequate remedy at law.
10. The complaint satisfied Rule 9(b) because it identified the who, what, where, when, and how of the alleged misrepresentations and omissions.

Questions Presented

1. Whether plaintiffs plausibly alleged Article III injury in fact by alleging that the Up&Up products they purchased manifested the alleged benzene defect.
2. Whether plaintiffs had standing to seek prospective injunctive and declaratory relief.
3. Whether the complaint plausibly alleged the Class Action Fairness Act's jurisdictional prerequisites.
4. Whether the FDCA expressly or impliedly preempted plaintiffs' state-law misbranding theory.
5. Whether plaintiffs plausibly pleaded adulteration based on benzene contamination.
6. Whether plaintiffs plausibly pleaded adulteration based on violations of current good manufacturing practices.
7. Whether the primary-jurisdiction doctrine required dismissal or a stay.
8. Whether the economic-loss rules of California, Illinois, and Nebraska barred the negligent-misrepresentation and negligent-omission claims.
9. Whether plaintiffs plausibly pleaded unjust enrichment as an alternative remedy.
10. Whether the complaint satisfied Federal Rule of Civil Procedure 9(b).

Disposition

other